Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.
about
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiencyAssociation between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.New hope for an AIDS vaccine.Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replicationNovel peptide-based HIV-1 immunotherapy.DNA vaccines against human immunodeficiency virus type 1 in the past decade.Nanotechnology Applications to HIV Vaccines and Microbicides.Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapyThirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapyA consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.HIV controllers: a genetically determined or inducible phenotype?Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virusReversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load.HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1.HIV-specific CD8+ T-cell proliferation is prospectively associated with delayed disease progression.Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressorsSafety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults
P2860
Q24652185-59AC487D-6E92-4642-8FC1-2D5EAB509615Q30379200-829DC731-890D-4A7C-BC75-EB9F7A96C07AQ33354070-587B56D6-F78B-4F03-9C4E-E8CB874901E0Q33604871-0C540386-71A3-45F3-9157-CA5231B05A58Q33648533-3026CDC2-307C-4E9F-B31C-2A7BCBAB276CQ33763297-ECCC1A66-F11E-48AC-B519-9E0C9891C394Q33803446-A624B081-9DFF-4AFA-99C9-A53EF36C6D3BQ33817504-D4A56581-A760-4F41-9D85-C372A651BCFAQ34007084-BB0C1383-7D31-4847-B7A4-281036B04311Q34052457-911CFD01-8193-44A5-BDF3-CC0A43C770E2Q34598141-0CC43B07-E0E7-486E-9176-F38E48B4BA8DQ34632063-1162A9F1-E499-45CE-9FD1-F6492AA18257Q34857689-DCC01C19-C3E6-4F09-AEBB-094D771BCD46Q35635247-6D8C7A72-3282-470D-AFB2-767CC1EFFDA0Q35684864-24E938B8-E6A0-4FFB-93D4-5FC6543074DDQ35745831-F464E7E9-1C7E-4EBF-A6C5-93F1248CEA1FQ35890514-499477F7-31E1-455C-B267-D118BAA96825Q35923609-CA74D49C-3FF1-4C8F-885C-B20400DAA1B6Q36010933-7D2C6B72-71CE-4C32-892B-6D83FA464CBFQ36524157-5470CF9E-9390-464E-9ECE-E46182C3C611Q37078512-B571ED84-393E-4B70-A01F-8B033F12D15EQ37309264-548B15D6-2B1D-4D9F-8869-AC4BF749FD1DQ37356652-672527A5-33BD-41E0-B3AB-C4766F8C704AQ37492797-64AA033C-58D2-4A1A-A9E2-9BC661A1AD06Q38114915-6DCA44CD-EC6F-4E3E-96DC-E62DF2475E53Q39596414-59D9AC0D-E327-4913-A968-9A8478FA5F80Q39601073-8AACAD7B-CEE0-447C-A14E-BD251793AF6FQ39605628-6732D7A1-B504-49A0-937E-6E054357F446Q39685522-6E123595-3428-48B8-A923-A3B1C428A42CQ42800282-6D112EF1-1FB8-4A00-84C1-00FD1FC80D4EQ45325097-662DD82C-709B-4091-A494-56A6B5DBD3B2Q54354367-32AA7CAA-04F0-4293-B240-663FE779F326Q58377836-771A8229-0A66-494C-96A2-08685564CD15Q58436528-A182D014-C0A2-4FEA-BB4C-C4CB79784752
P2860
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Longitudinal analysis of human ...... with nonprogressive infection.
@en
Longitudinal analysis of human ...... with nonprogressive infection.
@nl
type
label
Longitudinal analysis of human ...... with nonprogressive infection.
@en
Longitudinal analysis of human ...... with nonprogressive infection.
@nl
prefLabel
Longitudinal analysis of human ...... with nonprogressive infection.
@en
Longitudinal analysis of human ...... with nonprogressive infection.
@nl
P2093
P356
P1476
Longitudinal analysis of human ...... with nonprogressive infection.
@en
P2093
Kerkhof-Garde SR
Pontesilli O
Schuitemaker H
P304
P356
10.1086/515659
P407
P577
1998-10-01T00:00:00Z